Vertex Pharmaceuticals Inc (VRTX)

152.72
0.28 0.18
NASDAQ : Health Care
Prev Close 153.00
Open 153.29
Day Low/High 151.51 / 155.14
52 Wk Low/High 75.90 / 143.45
Volume 1.39M
Avg Volume 1.81M
Exchange NASDAQ
Shares Outstanding 252.12M
Market Cap 38.62B
EPS -0.50
P/E Ratio 148.74
Div & Yield N.A. (N.A)

Latest News

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Trade from the long side, but have a sell stop below $149 in case of a reversal.

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Appoints Tom Graney As Senior Vice President And Chief Financial Officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Announces Acceptance Of Its Applications For Review Of The Tezacaftor/Ivacaftor Combination Treatment In People With Cystic Fibrosis By The FDA And EMA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the acceptance of its applications for the use of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis (CF) ages 12 and...

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

The Seattle firm said Aug. 21 it completed an underwritten public offering of 3 million shares priced at $22.75 apiece.

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Investors, antsy about increased volatility in the markets, might look to high dividend yielding REITs to ride out the uncertainty.

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

FDA Approves KALYDECO® (ivacaftor) For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants

Let's examine VRTX's sharp decline today.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BA, CAI, CNHI, FFWM, FSV, NEP, NOW, TGI, TRK, TSU, WPG Downgrades: AAT, BLMN, FBR, GSK, HZO, QDEL, VRTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Reports Second-Quarter 2017 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017.

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are marginally higher on Wednesday ahead of an announcement from the Federal Reserve on interest rates.

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

The Nasdaq and S&P 500 ended at records for the second day in a row.

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq Hover at Session Highs, Apple on Pace for 9-Day Win Streak

S&P 500 and Nasdaq at record highs.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Biotech Movers: Vertex Continues to Move on Data for CF Regimen

Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.

Vertex Pharmaceuticals Stock Surging on Positive Trial Data

Vertex Pharmaceuticals Stock Surging on Positive Trial Data

Cystic fibrosis is an inherited disorder that causes damage to the lungs, digestive system, and other organs of the body.

Vertex Announces Positive Phase 1 & Phase 2 Data From Three Different Triple Combination Regimens In People With Cystic Fibrosis Who Have One F508del Mutation And One Minimal Function Mutation (F508del/Min)

Vertex Announces Positive Phase 1 & Phase 2 Data From Three Different Triple Combination Regimens In People With Cystic Fibrosis Who Have One F508del Mutation And One Minimal Function Mutation (F508del/Min)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del...

Vertex Awards Two First-Generation College Students Full Scholarships To The University Of Massachusetts

Vertex Awards Two First-Generation College Students Full Scholarships To The University Of Massachusetts

Vertex, Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in...

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Vertex To Announce Second Quarter 2017 Financial Results On July 26

Vertex To Announce Second Quarter 2017 Financial Results On July 26

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close.

Vertex Announces Reimbursement Agreement In Italy For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Announces Reimbursement Agreement In Italy For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) has agreed to reimburse ORKAMBI ® (lumacaftor/ivacaftor), the first...

3 Red-Hot Biotech Stocks That Could Get Even Hotter

3 Red-Hot Biotech Stocks That Could Get Even Hotter

An analyst weighs in.

How President Trump Has Sent Biotech Stocks Soaring

How President Trump Has Sent Biotech Stocks Soaring

The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.

You Will Live to 110 or 120 Years Old, So Don't Make This One Killer Mistake About Your Retirement

You Will Live to 110 or 120 Years Old, So Don't Make This One Killer Mistake About Your Retirement

You're thinking about your retirement all wrong.

TheStreet Quant Rating: C+ (Hold)